Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Other financing activities (2018 - 2022)

OptimizeRx's Other financing activities history spans 8 years, with the latest figure at $4.3 million for Q3 2022.

  • For Q3 2022, Other financing activities rose 324.33% year-over-year to $4.3 million; the TTM value through Sep 2022 reached $12.5 million, up 317.05%, while the annual FY2018 figure was $1.9 million, N/A changed from the prior year.
  • Other financing activities for Q3 2022 was $4.3 million at OptimizeRx, up from $4.0 million in the prior quarter.
  • Across five years, Other financing activities topped out at $4.3 million in Q3 2022 and bottomed at $408087.0 in Q2 2019.
  • The 5-year median for Other financing activities is $754512.0 (2020), against an average of $1.4 million.
  • The largest annual shift saw Other financing activities dropped 22.84% in 2021 before it soared 445.23% in 2022.
  • A 5-year view of Other financing activities shows it stood at $1.0 million in 2018, then plummeted by 54.34% to $469539.0 in 2019, then surged by 34.48% to $631453.0 in 2020, then skyrocketed by 59.63% to $1.0 million in 2021, then skyrocketed by 324.33% to $4.3 million in 2022.
  • Per Business Quant, the three most recent readings for OPRX's Other financing activities are $4.3 million (Q3 2022), $4.0 million (Q2 2022), and $3.2 million (Q1 2022).